Literature DB >> 23763575

A sensitive assay using a native protein substrate for screening HIV-1 maturation inhibitors targeting the protease cleavage site between the matrix and capsid.

Sook-Kyung Lee1, Nancy Cheng, Emily Hull-Ryde, Marc Potempa, Celia A Schiffer, William Janzen, Ronald Swanstrom.   

Abstract

The matrix/capsid processing site in the HIV-1 Gag precursor is likely the most sensitive target to inhibit HIV-1 replication. We have previously shown that modest incomplete processing at the site leads to a complete loss of virion infectivity. In the study presented here, a sensitive assay based on fluorescence polarization that can monitor cleavage at the MA/CA site in the context of the folded protein substrate is described. The substrate, an MA/CA fusion protein, was labeled with the fluorescein-based FlAsH (fluorescein arsenical hairpin) reagent that binds to a tetracysteine motif (CCGPCC) that was introduced within the N-terminal domain of CA. By limiting the size of CA and increasing the size of MA (with an N-terminal GST fusion), we were able to measure significant differences in polarization values as a function of HIV-1 protease cleavage. The sensitivity of the assay was tested in the presence of increasing amounts of an HIV-1 protease inhibitor, which resulted in a gradual decrease in the fluorescence polarization values demonstrating that the assay is sensitive in discerning changes in protease processing. The high-throughput screening assay validation in 384-well plates showed that the assay is reproducible and robust with an average Z' value of 0.79 and average coefficient of variation values of <3%. The robustness and reproducibility of the assay were further validated using the LOPAC(1280) compound library, demonstrating that the assay provides a sensitive high-throughput screening platform that can be used with large compound libraries for identifying novel maturation inhibitors targeting the MA/CA site of the HIV-1 Gag polyprotein.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23763575      PMCID: PMC3855639          DOI: 10.1021/bi4005232

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  66 in total

Review 1.  Structure-based discovery of Tipranavir disodium (PNU-140690E): a potent, orally bioavailable, nonpeptidic HIV protease inhibitor.

Authors:  S Thaisrivongs; J W Strohbach
Journal:  Biopolymers       Date:  1999       Impact factor: 2.505

2.  Structure of the immature retroviral capsid at 8 Å resolution by cryo-electron microscopy.

Authors:  Tanmay A M Bharat; Norman E Davey; Pavel Ulbrich; James D Riches; Alex de Marco; Michaela Rumlova; Carsten Sachse; Tomas Ruml; John A G Briggs
Journal:  Nature       Date:  2012-07-19       Impact factor: 49.962

Review 3.  HIV-1 assembly, budding, and maturation.

Authors:  Wesley I Sundquist; Hans-Georg Kräusslich
Journal:  Cold Spring Harb Perspect Med       Date:  2012-07       Impact factor: 6.915

4.  Polarization of the fluorescence of macromolecules. I. Theory and experimental method.

Authors:  G WEBER
Journal:  Biochem J       Date:  1952-05       Impact factor: 3.857

5.  Specific covalent labeling of recombinant protein molecules inside live cells.

Authors:  B A Griffin; S R Adams; R Y Tsien
Journal:  Science       Date:  1998-07-10       Impact factor: 47.728

6.  Betulinic acid and dihydrobetulinic acid derivatives as potent anti-HIV agents.

Authors:  Y Kashiwada; F Hashimoto; L M Cosentino; C H Chen; P E Garrett; K H Lee
Journal:  J Med Chem       Date:  1996-03-01       Impact factor: 7.446

7.  Measurement of specific protease activity utilizing fluorescence polarization.

Authors:  L M Levine; M L Michener; M V Toth; B C Holwerda
Journal:  Anal Biochem       Date:  1997-04-05       Impact factor: 3.365

8.  Proteolytic refolding of the HIV-1 capsid protein amino-terminus facilitates viral core assembly.

Authors:  U K von Schwedler; T L Stemmler; V Y Klishko; S Li; K H Albertine; D R Davis; W I Sundquist
Journal:  EMBO J       Date:  1998-03-16       Impact factor: 11.598

9.  Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease.

Authors:  S W Kaldor; V J Kalish; J F Davies; B V Shetty; J E Fritz; K Appelt; J A Burgess; K M Campanale; N Y Chirgadze; D K Clawson; B A Dressman; S D Hatch; D A Khalil; M B Kosa; P P Lubbehusen; M A Muesing; A K Patick; S H Reich; K S Su; J H Tatlock
Journal:  J Med Chem       Date:  1997-11-21       Impact factor: 7.446

10.  ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans.

Authors:  D J Kempf; K C Marsh; J F Denissen; E McDonald; S Vasavanonda; C A Flentge; B E Green; L Fino; C H Park; X P Kong
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-28       Impact factor: 11.205

View more
  3 in total

1.  Fluorescence polarization assays in high-throughput screening and drug discovery: a review.

Authors:  Matthew D Hall; Adam Yasgar; Tyler Peryea; John C Braisted; Ajit Jadhav; Anton Simeonov; Nathan P Coussens
Journal:  Methods Appl Fluoresc       Date:  2016-04-28       Impact factor: 3.009

2.  HIV-1 Protease Uses Bi-Specific S2/S2' Subsites to Optimize Cleavage of Two Classes of Target Sites.

Authors:  Marc Potempa; Sook-Kyung Lee; Nese Kurt Yilmaz; Ellen A Nalivaika; Amy Rogers; Ean Spielvogel; Charles W Carter; Celia A Schiffer; Ronald Swanstrom
Journal:  J Mol Biol       Date:  2018-11-07       Impact factor: 5.469

3.  Development of a Novel Screening Strategy Designed to Discover a New Class of HIV Drugs.

Authors:  Nancy Cheng; Sook-Kyung Lee; P Scott Donover; Mel Reichman; Celia A Schiffer; Emily A Hull-Ryde; Ronald Swanstrom; William P Janzen
Journal:  J Lab Autom       Date:  2013-12-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.